Clinical trials: Sirolimus, completed
PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome
RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome
Phosphatase and TENsin homolog (PTEN) gene germline mutations are associated with a spectrum of clinical manifestations characterized by neurocognitive deficits, intellectual disability, autism symptomatology, skin lesions…
- Trial name
- NCT02991807
- Testing
- RAD001
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- Boston Children's Hospital
Solid Tumors
Erlotinib and Temsirolimus for Solid Tumors
Define the maximum tolerated dose and dose limiting side-effects of temsirolimus in combination wtih erlotinib in patients with resistant solid tumors
- Trial name
- NCT00770263
- Testing
- Erlotinib, Temsirolimus
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Washington University School of Medicine
Coronary Artery Disease
Sirolimus-Eluting BX VELOCITYTM Balloon-Expandable Stent in a Compassionate Use Registry (SECURE)
The objective of this study is to allow treatment with the sirolimus-eluting Bx VELOCITYTM stent in patients with a serious disease or condition for which there is no generally acceptable alternate treatment available.
- Trial name
- NCT00231244
- Testing
- CYPHER Sirolimus-Eluting Coronary Stent
- Where
- United States
- Volunteers
- 252 people
- Sponsor
- Cordis US Corp.
Schizophrenia
Inpatient Evaluation of Adults With Schizophrenia
The purpose of this study is to understand the biologic basis of schizophrenia and to determine which symptoms are related to the illness itself and which are related to medications used to treat the illness.
- Trial name
- NCT00001247
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 648 people
- Sponsor
- National Institute of Mental Health (NIMH)
Recurrent Mantle Cell Lymphoma
CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma
Phase II trial to study the effectiveness of CCI-779 in treating patients who have mantle cell non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00033267
- Testing
- temsirolimus
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Absence; Kidney
Sirolimus Conversions in African-American Renal Transplant Recipients
This study's focus is to compare the level effectiveness and safety of regimens involving Sirolimus, Cellcept and steroid to Prograf, Sirolimus and steroid in African-American recipients of kidney transplants.
- Trial name
- NCT01005706
- Testing
- rapamune, mycophenolate mofetil and steroid, tacrolimus, sirolimus and steroid
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Medical University of South Carolina
Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
The purpose of the study is to compare the clinical benefit, as measured by duration of overall survival, of Nivolumab vs. Everolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who have received prior…
- Trial name
- NCT01668784
- Testing
- Nivolumab, Everolimus
- Where
- 168 sites in United States, Argentina and 22 more
- Volunteers
- 821 people
- Sponsor
- Bristol-Myers Squibb
Neoplasms, Breast Neoplasms
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
Dose escalation part: to determine the highest dose of alpelisib administered on a daily basis when given in combination with daily everolimus or in combination with daily everolimus and exemestane.
- Conditions
- Neoplasms, Breast Neoplasms, Kidney Neoplasms, Pancreatic Neuroendocine Neoplasms (pNETs)
- Trial name
- NCT02077933
- Testing
- alpelisib, everolimus, exemestane
- Where
- 22 sites in United States, France and 7 more
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Type 1 Diabetes, Hypoglycemia
Delayed Mycophenolate Mofetil in Single-Donor Islet Allotransplantation in Type 1 Diabetes
The objective of this study is to assess the safety and efficacy of islet allotransplantation for the reestablishment of stable glycemic control in patients with type 1 diabetes, using anti-thymocyte globulin induction…
- Trial name
- NCT00285233
- Testing
- Allogeneic islets of Langerhans transplant
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Retinal Astrocytic Hamartoma
Sirolimus for Retinal Astrocytic Hamartoma
A single patient study using intravitreal Sirolimus to treat a patient with multiple retinal astrocytic hamartomas (RAH) of both eyes.
- Trial name
- NCT04707209
- Testing
- Sirolimus
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- The Hospital for Sick Children
Refractory Solid Tumors
Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors
This study is a single arm, pilot study of sirolimus in patient with Phosphatidylinositide-3-kinase (PIK3CA) mutation, PIK3CA amplification , PIK3CA-AKT pathway aberration Refractory solid tumor and/or specific sensitivity to…
- Trial name
- NCT02688881
- Testing
- sirolimus
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Samsung Medical Center
Coronary Artery Disease
Supralimus-Core™ Pharmacokinetic (PK) Study
The primary objective of this study is to evaluate the pharmacokinetic (PK) and safety associated with Supralimus-Core™ Sirolimus Eluting Coronary Stent system in the treatment of single de novo lesions in native coronary…
- Trial name
- NCT01121744
- Testing
- Supralimus-Core™ Sirolimus eluting Coronary Stent
- Where
- 4 sites in India
- Volunteers
- 20 people
- Sponsor
- Sahajanand Medical Technologies Limited
Exudative Age Related Macular Degeneration
Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD
To determine safety and efficacy of intravitreal injections of Sirolimus with adjunct EYLEA in subjects with exudative age related macular degeneration (AMD) with persistent intraretinal or subretinal edema due to neovascular AMD…
- Trial name
- NCT02732899
- Testing
- Sirolimus, EYLEA
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Maturi, Raj K., M.D., P.C.
Familial Adenomatous Polyposis
Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance
Patients with Familial Adenomatous Polyposis (FAP) who are undergoing endoscopic surveillance will be given Encapsulated Rapamycin (eRapa) at one of three escalating doses/schedules for 12 months with the aim of reducing polyp…
- Trial name
- NCT04230499
- Testing
- Encapsulated Rapamycin (eRapa)
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Rapamycin Holdings Inc.
Inclusion Body Myositis (IBM)
Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis
Sporadic Inclusion Body Myositis (IBM) is the most frequent inflammatory myopathy in patients over 50. It is a slowly progressive, but today untreatable (notably by classical immunosuppressants) disease.
- Trial name
- RAPAMI (NCT02481453)
- Testing
- Rapamycin
- Where
- France
- Volunteers
- 44 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Prostatic Neoplasms
An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients
Open-label exloratory pharmacodynamic and pharmacogenomic study to evaluate teh biologic effects of 3 dose levels (1mg, 5 mg, and 15 mg) of temsirolimus administered orally once daily for approximately 4 weeks (+/- 2 weeks)…
- Trial name
- NCT00235794
- Testing
- temsirolimus
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Mouth Neoplasms, Head and Neck Neoplasms
Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma
Background: Advanced-stage head and neck cancer (head and neck squamous cell carcinoma [HNSCC]) has moderately successful treatment outcomes, usually involving surgery as part of the standard treatment.
- Conditions
- Mouth Neoplasms, Head and Neck Neoplasms, Tongue Neoplasms, Carcinoma, Squamous Cell
- Trial name
- NCT01195922
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Pancreatic Cancer
Sirolimus in Treating Patients With Advanced Pancreatic Cancer
RATIONALE: Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well sirolimus works in treating patients with advanced pancreatic…
- Trial name
- NCT00499486
- Testing
- sirolimus
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Endometrial Carcinoma, Recurrent Uterine Corpus Carcinoma
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
This randomized phase II trial studies how well temsirolimus with or without megestrol acetate and tamoxifen citrate works in treating patients with endometrial cancer that has spread to other places in the body and usually…
- Conditions
- Endometrial Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Uterine Corpus Cancer
- Trial name
- NCT00729586
- Testing
- Laboratory Biomarker Analysis, Megestrol Acetate, Tamoxifen Citrate
- Where
- 108 sites in United States
- Volunteers
- 73 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer
Anthracycline-taxane based chemotherapy regimens are recommended mainly by current guidelines for neoadjuvant application of systemic treatment. The addition of other cytotoxic agents, e.g.
- Trial name
- GeparQuinto (NCT00567554)
- Testing
- epirubicin - cyclophosphamide / docetaxel, epirubicin - cyclophosphamide / docetaxel + bevacizumab, paclitaxel
- Where
- Germany
- Volunteers
- 2,600 people
- Sponsor
- GBG Forschungs GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.